[1] Smelov V,Krylova T,Smelova N,et al.Azithromycin treatment follow-up:antibacterial susceptibility of Chlamydia trachomatis in patients with chronic prostatitis.Int J Antimicrob Agents,2004,23Suppl 1:S79-82. [2] Samra Z,Rosenberg S,Soffer Y,et al.In vitro susceptibility of recent clinical isolates of Chlamydia trachomatis to macrolides and tetracyclines.Diagn Microbiol Infect Dis,2001,39:177-179. [3] 白桦,佟菊贞,宁波,等.泌尿生殖道沙眼衣原体对19种抗生素敏感性的研究.中华医学杂志,1994,74:11-14. [4] 韩建德,张云青,廖绮曼,等.泌尿生殖道沙眼衣原体体外药物敏感性测定.中国抗生素杂志,2002,27:441-442. [5] Somani J,Bhullar VB,Workowski KA,et al.Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure.J Infect Dis,2000,181:1421-1427. [6] 尚淑贤,王千秋.沙眼衣原体抗生素敏感性试验及临床耐药研究中华皮肤科杂志,2003,36:540-542. [7] Takahashi S,Hagiwara T,Shiga S,et al.In vitro analysis of the change in resistance of Chlamydia trachomatis under exposure to sub-MIC levofloxacin for a therapeutic term.Chemotherapy,2000,46:402-407. [8] Dessus-Babus S,Bebear CM,Charron A,et al.Sequencing of gyrase and topoisomerase Ⅳ quinolone-resistance-determining regions of Chlamydia trachomatis and characterization of quinolone-resistant mutants obtained In vitro.Antimicrob Agents Chemother,1998,42:2474-2481. |